Sarepta Therapeutics (SRPT) Stock

A jury in Delaware announced on Friday that Japanese pharmaceutical company Nippon Shinyaku violated a Sarepta patent connected to its DMD drug, Vyondys 53, and is required to pay $115.2 million in damages.

The phase III EMERGENE study is looking into Sarepta's new gene therapy for a very rare muscle disorder that currently has no cure, only treatments to manage symptoms.

Analysts at Jefferies think that the new guidance from the Food and Drug Administration (FDA) on accelerated approval for drugs aimed at "serious conditions" is a good development for rare diseases. Earlier this month, the FDA released a draft of its policies and procedures for the accelerated approval pathway for drugs that address unmet medical needs.

The average price target suggests that Sarepta Therapeutics (SRPT) could increase by 48%. Although studies indicate that this measure is not very reliable, an increase in earnings estimate revisions might indicate that the stock could rise soon.

The increase in SRPT's stock price is due to the positive sales results of its newly approved one-time gene therapy for DMD.

Analysts' average price targets for Sarepta Therapeutics (SRPT) suggest that the stock could increase by 42.1%. Although this popular measure hasn't always been very reliable, the consensus among analysts to raise earnings forecasts does suggest potential growth for the stock.

Sarepta has obtained the rights to four programs that are in clinical stages and three that are in preclinical stages, focusing on muscle disorders, central nervous system issues, and rare lung diseases.

Sarepta Therapeutics, Inc. announced that its net product revenues for the third quarter of 2024 reached $429.8 million, marking a 39% increase compared to the previous year, mainly due to robust sales of ELEVIDYS and other treatments for DMD. The company is also progressing with its SRP-9003 gene therapy for LGMD, with results from a phase 3 study anticipated in early 2025 and a possible BLA submission by mid-2025. However, despite these strong revenues, Sarepta may need to secure additional funding in the next year to continue its operations and development projects.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will hold its Q3 2024 Earnings Conference Call on November 6, 2024, at 4:30 PM ET. The call will feature several company executives, including the President and CEO, Douglas Ingram, and the Chief Financial Officer, Ian Estepan. Following their presentations, there will be a session for questions from conference call participants.